Our study revealed that a high proportion of B lymphocytes and a high CD8-to-CD20 lymphocytes ratio in the tumor microenvironment were associated with a positive response to Pembrolizumab and Lenvatinib therapy. The gene discussed is CD8A; the disease is neoplasm.